Mucopolysaccharidosis - Causes, Treatment & When to See a Doctor

What is Mucopolysaccharidosis?

Mucopolysaccharidosis (MPS) is a rare group of inherited disorders caused by deficiencies in specific enzymes needed to break down sugar molecules called glycosaminoglycans (GAGs). These substances are essential for building connective tissues, including cartilage, tendons, and skin. When GAGs accumulate due to enzyme deficiencies, they can damage organs and tissues throughout the body, leading to a range of physical and developmental challenges. MPS is classified into several types (I-X), each caused by a different enzyme defect and presenting with varying severities.

According to the National Institutes of Health (NIH), MPS is often diagnosed in childhood but can vary widely in symptoms from mild to life-threatening. Early diagnosis is critical for managing the condition, though there is no cure. Treatment focuses on slowing progression and addressing symptoms through therapies like enzyme replacement therapy (ERT) or supportive care.

Common Causes

MPS is not caused by infections or lifestyle factors but by genetic mutations affecting specific lysosomal enzymes. Below are the primary types of MPS and their associated enzyme deficiencies:

• MPS I (Hurler, Hurler-Scheie, Scheie syndromes): Deficiency in alpha-L-iduronidase, leading to different subtypes based on severity.
• MPS II (Hurler-Nickenbeck syndrome): Deficient-performance of beta-glucuronidase.
• MPS III (Sanfilippo syndromes A-D): Four subtypes due to deficiencies in enzymes involved in N-acetylgalactosamine breakdown.
• MPS IV (Morquio syndromes A-B): Caused by deficiencies in enzymes that process keratan sulfate.
• MPS VI (Maroteaux-Lamy syndrome): Deficiency in arylsulfatase B.
• MPS VII (Bathe-S نے syndrome): Caused by deficiency in beta-hexosaminidase.
• MPS IX: Rare subtype due to deficiencies in enzymes involved in keratan sulfate metabolism.
• Other rare MPS types: Include MPS X (Lysosomal storage disorder due to deficiency in arylsulfatase D) and MPS XI.
• MPS XII: Also known as Fabry disease (though sometimes classified separately).

As noted by the Rare Disease Foundation, these genetic mutations are inherited in an autosomal recessive pattern, meaning both parents must pass on the defective gene for a child to be affected.

Associated Symptoms

Symptoms of MPS vary by type and severity but often include physical, developmental, and systemic issues. Common signs include:

• Coarse facial features: Enlarged teeth, a flat nasal bridge, and thickened skin.
• Skeletal abnormalities: Short stature, curved spines (kyphoscoliosis), and joint dislocations.
• Organ enlargement: Liver or spleen enlargement due to GAG buildup.
• Developmental delays: Delayed motor skills, speech, or intellectual impairment (more common in severe types like Hurler syndrome).
• Vision and hearing loss: Cataracts or lens clouding (vision issues); chronic ear infections (hearing loss).
• Respiratory problems: Recurrent infections, sleep apnea, or chronic cough.
• Hernias: Umbilical or inguinal hernias due to weak abdominal muscles.
• Feeding difficulties: Poor muscle tone or dysphagia (swallowing problems).

The Cleveland Clinic notes that mild types like MPS VI often have fewer developmental issues, while severe forms like MPS I can be fatal in adulthood without treatment.

When to See a Doctor

Early evaluation is crucial for MPS, especially if a child exhibits signs like:

• Unusual facial features or physical growth delays.
• Developmental regression or severe delays in motor skills.
• Recurrent ear infections or vision problems.
• Respiratory distress or recurrent infections.
• Unexplained weight gain or rapid growth in infancy.

Parents or caregivers should also seek immediate medical attention if the child experiences acute symptoms such as high fever, severe cough, or respiratory failure, which may indicate life-threatening complications like mucopolysaccharidosis-associated chest syndrome.

The CDC recommends consulting a geneticist or rare disease specialist if symptoms persist or worsen, as early intervention improves outcomes.

Diagnosis

Diagnosing MPS involves a combination of clinical evaluation, biochemical tests, and genetic analysis:

1. Physical exam: Doctors assess for characteristic signs like coarse features or organ enlargement.
2. Blood or urine tests: Elevated levels of GAGs (e.g., dermatan sulfate) confirm enzyme deficiencies.
3. Genetic testing: Identifies specific mutations in genes responsible for MPS types.
4. Imaging: X-rays or MRIs may reveal skeletal abnormalities or organ enlargement.

The National Organization for Rare Disorders (NORD) emphasizes that early genetic testing is key to differentiating MPS types and tailoring treatment.

Treatment Options

While there is no cure for MPS, several treatments can manage symptoms and slow disease progression:

• Enzyme Replacement Therapy (ERT): Administered intravenously for types like MPS I, II, VI, and VII. ERT helps reduce GAG accumulation but is costly and requires frequent infusions.
• Substrate Reduction Therapy (SRT): Uses drugs like miglustat to limit GAG production in cells (effective for MPS III and IV).
• Supportive care: Includes physical therapy for joint mobility, speech therapy for communication, and nutritional support for developmental delays.
• Surgical interventions: Corrective surgeries for hernias, joint dislocations, or airway obstructions.
• Home management: Monitoring for respiratory infections, maintaining hydration, and managing pain with medications.

ERT can significantly improve quality of life, but access varies due to cost and insurance coverage. The World Health Organization recommends ERT for eligible patients but stresses the need for healthcare system support.

Prevention Tips

MPS is genetic, so prevention focuses on early diagnosis and family planning:

• Genetic counseling: For families with a history of MPS to assess risks and understand inheritance patterns.
• Prenatal testing: Amniocentesis or chorionic villus sampling can detect MPS in unborn children.
• Carrier testing: For partners of individuals with MPS to identify gene carriers.
• Regular monitoring: For affected individuals, regular check-ups to manage complications early.

The Mayo Clinic advises that while MPS cannot be prevented in those born with the condition, proactive care can mitigate its impact.

Emergency Warning Signs